Back to results
US 2024/0199699 A1Published application
Nicotinic acetylcholine receptor peptide antagonist conotoxin compositions and related methods
AssigneeGlo Pharma, Inc.
InventorRobert A. LOVE
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel peptide antagonists that inhibit binding of acetylcholine to the active site of the muscle-type nicotinic acetylcholine receptor. The peptide antagonists of the invention are useful in cosmetic compositions that prevent or improve the appearance of skin wrinkles and related skin conditions. The invention further relates to cosmetic and pharmaceutical compositions comprising a peptide antagonist of the invention, and methods for their use.
Claims19
-21. (canceled)
A muscle-type nicotinic acetylcholine receptor peptide antagonist comprising an amino acid sequence:
- Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-
- Xaa11-Xaa12-Xaa13-Xaa14
- wherein:
- Xaa1 is absent;
- Xaa2 is absent;
- Xaa3 and Xaa8 form a linkage Xaa3-Xaa8;
- Xaa4 and Xaa14 form a linkage Xaa4-Xaa14;
- Xaa5 is selected from:
- Asn, Asp, Gln, Glu, Arg, and Lys;
- Xaa6 is selected from:
- Pro and hydroxyproline;
- Xaa7 is selected from:
- Ala, Gly, Val, Leu, and Ile;
- Xaa9 is selected from:
- Ala, Gly, Val, Leu, and Ile;
- Xaa10 is selected from:
- Arg, His, and Lys;
- Xaa11 is selected from:
- Asn, Asp, Gln, Glu, Arg, and Lys;
- Xaa12 is selected from:
- Phe, Trp, and Tyr;
- Xaa13 is selected from:
- Cys, Met, Sec, Ser, Thr, Arg, His, and Lys;
- the N-terminus is optionally modified;
- and
- the C-terminus is optionally modified.
23 more elements
Dependencies are inferred from the claim text.